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Introduction: Pineal region glioblastoma multiforme (GBM) is a rare disease entity with 
a generally poor prognosis. We present a case of a patient with an unresectable pineal 
region GBM treated with chemoradiation with favorable outcome.
Case background: A 65-year-old patient who was presented with visual symptoms 
was found to have a pineal region tumor on imaging. A stereotactic biopsy showed a 
World Health Organization Grade IV GBM, O-6-methylguanine-DNA methyltransferase 
(MGMT) promoter methylated, isocitrate dehydrogenase 1 and 2 wild type. The patient 
was treated with radiotherapy with concurrent temozolomide, followed by adjuvant 
temozolomide. Disease progression occurred at 58 weeks post-biopsy, which prompted 
the initiation of bevacizumab. The patient was alive and functioning well as of his last 
follow up, 166 weeks from the initial biopsy.
Discussion: On our review of the literature, 24 cases of pineal region GBM have been 
reported. The median reported survival for these previously reported cases was 6 months 
(range, 2–24 months). This patient has the longest overall survival reported to date for a 
patient with this diagnosis. This is the first patient in the literature with pineal region GBM 
who has been reported to have MGMT promoter methylation.
Concluding remarks: Although pineal region GBM is a rare disease entity with a gener-
ally poor prognosis, long-term survival is achievable for select patients. MGMT promoter 
methylation may potentially have prognostic value. Favorable control of recurrent disease 
with the use of bevacizumab is possible.
Keywords: pineal, glioblastoma, radiotherapy, temozolomide, O-6-methylguanine-DNa methyltransferase, 
bevacizumab
INtRoDUCtIoN
Various tumor histologies can arise in the pineal region, including parenchymal tumors, neu-
roectodermal tumors, germ cell tumors, and meningeal tumors (1). Gliomas in the pineal region 
include fibrillary astrocytoma, pilocytic astrocytoma, anaplastic astrocytoma, glioblastoma, oligo-
dendroglioma, ependymoma, and choroid plexus papilloma (2). Glioblastoma multiforme (GBM) 
is rarely found in the pineal region. This paper presents a case of primary GBM in the pineal region 
and discusses the clinical course, radiological findings, and treatment approaches with a review 
Abbreviations: GBM, glioblastoma multiforme; IMRT, intensity-modulated radiation therapy; MGMT, O-6-methylguanine-
DNA methyltransferase; IDH, isocitrate dehydrogenase, WHO, World Health Organization.
FIGURe 1 | Axial (a) and sagittal (B) T1 post-contrast and T2 fluid attenuated inversion recovery (C) images of the tumor at initial presentation.
FIGURe 2 | Hematoxylin and eosin stains of the tumor, showing necrosis at 20× (a), mitotic figures at 40× (B), and microvascular proliferation at 40× (C).
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of the relevant literature. The patient provided written informed 
consent for his personal information to be used for research and 
publication.
Case BaCKGRoUND
A 64-year-old male with no significant past medical history 
presented with vertical diplopia, headaches for 3  weeks, and 
6  months of insomnia. His neurological examination revealed 
a right cranial nerve IV palsy and gait difficulties. Subsequent 
CT imaging, 1 month after initial presentation, revealed a poorly 
marginated, hyperdense mass located in the pineal region. A 
CT of the chest, abdomen, and pelvis, and an MRI of the total 
spine showed no evidence of metastatic disease. MRI of the brain 
revealed a heterogeneously enhancing pineal mass measuring 
2.3  cm ×  2.5  cm ×  2.3  cm (Figure  1). The lesion was deemed 
unresectable due to its location and an image-guided stereotactic 
needle biopsy was performed. The pathology revealed a high-
grade glioma composed of markedly atypical cells, many with 
giant nuclei and containing abundant mitotic activity (seven 
mitoses in three high-powered fields), multiple foci of micro-
vascular proliferation, and areas of pseudopalisading necrosis, 
consistent with GBM, World Health Organization Grade IV 
(Figure  2). The tumor was positive for O-6-methylguanine-
DNA methyltransferase (MGMT) methylation and negative for 
isocitrate dehydrogenase 1/2 mutations. The patient’s GBM was 
treated with concurrent chemoradiation followed by adjuvant 
chemotherapy (3, 4). The patient received intensity-modulated 
radiation therapy consisting of 60  Gy in 2  Gy daily fractions 
with concurrent temozolomide at 75  mg/m2. The initial fields 
were treated to a dose of 50 Gy and encompassed a 2 cm margin 
along white matter tracts from the enhancing tumor and the sur-
rounding edema, and also covered the third and fourth ventricles, 
lateral ventricles, cerebral aqueduct, tectum, partial thalamus, 
and partial brainstem in the clinical target volume. The majority 
of the lateral ventricles were covered but the extreme ends of the 
horns were excluded due to concerns of additional toxicity, given 
the volume of brain treated, the prepontine cistern was not spe-
cifically targeted. An effort was made to cover the majority of the 
ventricles based on prior clinical reports describing a propensity 
for leptomeningeal spread of disease for pineal region GBMs. 
This initial radiotherapy plan was followed by a boost of 10 Gy 
to the enhancing tumor with a 2 cm margin along white matter 
tracts. The combined radiotherapy plan is displayed in Figure 3. 
The patient was placed on dexamethasone during the course of 
radiotherapy due to concerns that radiotherapy may potentially 
worsen local edema which could then result in obstruction of the 
cerebral aqueduct.
The patient developed alopecia and Common Terminology 
Criteria for Adverse Events version 4 Grade 1 dermatitis during 
the course of chemoradiation, but otherwise tolerated his concur-
rent chemoradiation well. Daily CT scans were used for radio-
therapy image guidance and showed no signs of hydrocephalus 
developing during treatment. An MRI 4 weeks after completion 
of radiotherapy showed a slight decrease in the size of the pineal 
GBM to 2.3 cm × 2.0 cm × 1.9 cm. He continued on maintenance 
FIGURe 3 | Axial and sagittal views of the dose distribution of the radiotherapy plan with the dose-volume histogram.
FIGURe 4 | Axial (a) and sagittal (B) T1 post-contrast and T2 fluid attenuated inversion recovery (C) images of the tumor at last follow up, 166 weeks following the 
initiation of chemoradiation.
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therapy with temozolomide, 5 days out of every 28 days per cycle, 
at 150 mg/m2 for the first cycle and increased to 200 mg/m2 for 
subsequent cycles.
An MRI was performed at 58 weeks post-biopsy that showed 
two new lesions in the brainstem and parietal lobe, both within 
the prior radiotherapy fields. A total spine MRI did not reveal any 
drop metastases, nor was there any indication of CSF dissemina-
tion per lumbar puncture. Bevacizumab 7.5 mg/kg every 3 weeks 
was added to the temozolomide therapy (5). Temozolomide was 
discontinued after 17 cycles, a total of 88 weeks after the biopsy. 
Due to clinical symptoms of worsening gait disturbance, which 
corresponded to MRI findings suspicious for infarct within the 
radiotherapy fields, at 129 weeks post-biopsy, bevacizumab was 
discontinued and serial MRIs were subsequently performed every 
2  months to closely monitor his disease. The MRI performed 
146 weeks after the initial biopsy, when compared over multiple 
prior studies dating back to 111  weeks post-biopsy, showed 
subtle, progressive increase in size of the pineal mass from 
11 mm × 11 mm to 14 mm × 11 mm and a confluent perive-
ntricular white matter T2/fluid attenuated inversion recovery 
hyperintensity that is non-specific and stable, this was redemon-
strated in his MRI at 166 weeks after biopsy (Figure 4).
Clinically, the patient continues to have double vision, which 
is corrected by prism glasses. The diplopia continues to cause gait 
disturbance, which has improved with physical therapy and the 
patient no longer requires the use of a cane. He was last seen in 
clinic 166 weeks following his biopsy and 156 weeks following the 
initiation of chemoradiation for a follow up. He was continuously 
monitored closely off systemic therapy.
DIsCUssIoN
Tumors of the pineal region are uncommon intracranial neo-
plasms. The most common glioma in the pineal region is a well-
differentiated astrocytoma (1). GBM, though common in the 
brain as a whole, is rarely seen in the pineal region. Since the first 
report on primary pineal GBM by Bradfield and Perez in 1972, 24 
case reports have been described (6–23) (Table 1).
The clinical symptoms associated with the presentation of a 
pineal GBM are associated with compression of adjacent structures. 
Of the 24 patients described in literature, 66.7% presented with 
signs or symptoms of increased intracranial pressure, and 41.7% 
also presented with visual disturbances including diplopia, 
nystagmus, and blurry vision, which may be associated with 
Parinaud’s syndrome. CT scans of pineal GBM typically show 
heterogeneously contrast-enhancing masses with zones of low 
density. Pineal region GBM is shown to infiltrate the leptome-
ninges with 33.3% of patients in the literature.
Of the 24 cases in the literature, 54.1% have a survival 
duration of less than 11 months, and 70.8% having a survival 
duration of less than 24 months. Of the 18 patients where sur-
vival was reported (excluding our current patient), the median 
taBLe 1 | Summary of published cases of pineal region glioblastoma.
Reference age sex symptoms Radiographic findings Leptomeningeal 
dissemination
treatment survival
Bradfield et al. (6) 53 F N/A HCP, mass in posterior third ventricle No (autopsy) Resection Post-operative 
death
Bradfield et al. (6) 5 F N/A HCP, mass in posterior third ventricle No (autopsy) Shunt 27 months
DeGirolami et al. (8) 3 cases Increased ICP, vertical gaze palsy in one N/A N/A RT for all three cases,  
resection for one
N/A
Kalyanaraman (12) 68 F Ataxia, confusion, urinary incontinence,  
upgaze limitation
CT: HCP, calcified midline mass N/A Resection, RT 4 months
Norbut et al. (13) 36 F HA, blurry vision, Parinaud’s Syndrome CT: HCP, mass in posterior third ventricle Yes Shunt, RT 4 months
Frank et al. (10) 52 F Intracranial ICP, oculomotor disturbances HCP, mass in third ventricle N/A Stereotactic biopsy, RT 4 months
Edwards et al. (9) 12 F N/A N/A N/A Resection, RT, chemo 18 months
Vaquero et al. (17) 63 F HA, behavioral changes CT: rounded hyperdense, mass with ring  
enhancement
N/A Shunt, resection, whole  
brain RT
6 months
Pople et al. (14) 6 F HA, N/V, diplopia, decreased visual acuity,  
CN VI palsy, upgaze limited
CT and MRI: HCP, enhancing mass Yes Shunt, resection, local RT, 
chemo
4 months
Cho et al. (7) 63 M Increased ICP, changing behavior HCP, hyperdense pineal mass with enhancement N/A Resection, RT 6 months
Gasparetto et al. (11) 29 F HA, drowsiness, fever, dizziness, seizure CT and MRI: ill-defined heterogeneously enhanced mass  
with extension to thalamus
No Shunt, resection 2 months
Toyooka et al. (15) 49 M HA, diplopia, memory disturbance MRI: HCP, irregular heterogeneously enhanced mass Yes Shunt, resection, chemo 
(ACNU), local RT
11 months
Amini et al. (16) 40 M HA, N/V, diplopia, blurry vision CT: obstructive HCP, strong enhancement, punctuate  
calcification MRI: heterogeneously enhancing with  
central necrosis, extension into midbrain
Yes Endoscopic TVB, resection, 
shunt, whole brain RT, chemo 
(temozolomide)
5 months
Amini et al. (16) 43 M Ha, disequilibrium, decreased level of  
mental status
MRI: heterogeneously enhancing, HCP Yes TVB, resection, whole  
brain RT, chemo
7 months
Amini et al. (16) 52 F HA, N/V, diplopia, blurry gaze palsy MRI: heterogeneously enhancing with central  
necrosis, obstructive HDC
Yes Endoscopic TVB, RT 2 months
Moon et al. (20) 68 M HA, N/V, ataxia CT: HCP, hypodense mass MRI: irregular heterogeneously  
ring-enhanced mass with central necrosis
Yes Resection, shunt 2 months
Ozgural et al. (18) 60 M HA, ataxia CT: triventricular HCP, isodense rounded mass MRI: 
heterogeneous, contrast enhanced mass
N/A RT, chemo 24 months
Mansour et al. (21) 69 M Altered mental status, vertigo CT and MRI: heterogeneous mass, HCP N/A Biopsy, chemo, RT 16 months
Suzuki et al. (22) 65 M Disturbed consciousness CT: intraventricular hemorrhage, HCP N/A Resection, RT, chemo N/A
Sugita et al. (23) 52 F HA, memory disturbance MRI: mass in pineal, HCP N/A Resection, RT, chemo 24 months
Sugita et al. (23) 18 M HA, CN VI palsy MRI: mass in the pineal, HCP N/A Resection, RT, chemo 13 months
Liu et al. (19) 30 M HA, vomiting, LE numbness MRI: multifocal lesion largest at the right  
thalamus
N/A Resection, RT, chemo N/A
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survival was 6 months (range, 2–24 months). Only one other 
patient has survived longer than 2 years. The maximum sur-
vival duration documented is the case presented in this report, 
with a survival time of 38 months at the time of manuscript 
preparation.
Pineal GBM is generally associated with a poor prognosis. 
Of the three cases that were treated with radiotherapy alone, the 
median survival was 3.5 months (range, 0–4 months) (10, 13, 16). 
The three patients in the literature treated with surgery alone had 
a median survival of 1.5  months, with a maximum survival of 
2 months (6, 11, 20). Patients treated with resection followed by 
radiotherapy had a slightly higher median survival of 5.5 months 
(range, 4–6 months) (7, 12, 17). A tri-modal treatment approach 
of surgical resection followed by chemotherapy and radiotherapy 
yielded a median survival time of 12 months (range, 4–24 months) 
among the cases reported thus far in the literature (9, 14–16, 
21, 23). However, those patients who received radiotherapy and 
chemotherapy without resection, including the present case, 
had the highest median survival duration of 20 months (range, 
7–36 months) (16, 18, 21).
It is unknown why patients who did not undergo resection 
appear to have had a more favorable outcome in this review, 
indeed the difficulty of achieving a gross total resection in tumors 
located in this region is thought to be one of the factors that 
contribute to the poor prognosis of tumors in this region (7, 18, 
20, 21), in addition to the propensity for pineal region GBMs to 
exhibit leptomeningeal spread of disease (13, 16, 21, 24), and the 
fact that progressive disease in this region could quickly affect 
critical structures in proximity to the pineal gland (16, 24). It may 
be possible that any attempt at resection could increase the risk 
of leptomeningeal seeding, and perhaps coverage of a significant 
volume of the ventricles in the radiotherapy plan as was done in 
this patient could aid in sterilizing leptomeningeal disease, but 
these hypotheses need to be studied in more detail.
O-6-methylguanine-DNA methyltransferase promoter meth-
ylation predicts for better outcomes for patients with GBM in 
other locations in the brain, including patients with an 
unresectable GBM (24). Our patient’s favorable outcome is likely 
associated with his MGMT promoter methylation status. To our 
knowledge, this is the first reported pineal GBM with MGMT 
promoter methylation. In prior literature, the methylation status 
was either not reported or was negative. A comparison of survival 
times of patients treated with chemoradiation based on MGMT 
promotor status would be valuable once more cases are reported, 
the results may lend more support to the premise that reason-
able survival outcomes can be achieved with chemoradiation in 
MGMT promoter methylated patients in the absence of gross 
total resection.
Based on the literature review performed for this report, 
there is no reported utilization of bevacizumab in patients with 
pineal region GBM. Our patient had an excellent response to 
bevacizumab with good long-term control of disease after initial 
progression, which has contributed to his good overall survival. 
This favorable response reflects data seen in cases of recurrent 
GBM outside of the pineal region (5).
CoNCLUDING ReMaRKs
Pineal GBM is a rare disease that is associated with a poor prog-
nosis. The majority of patients present with signs of increased 
intracranial pressure and visual symptoms. It is difficult to draw 
conclusions from the small number of total patients reported 
over a number of decades with differing treatment paradigms. 
This is the first pineal region GBM that reports positive MGMT 
promoter methylation and use of bevacizumab upon progres-
sion. Our case suggests that durable control of the disease can 
potentially be achieved in the absence of a gross total surgical 
resection. Further research in the role of MGMT methylation as 
a prognostic indicator and of the response of pineal region GBM 
to bevacizumab is warranted.
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